Lieberman A, Kupersmith M, Neophytides A, Casson I, Durso R, Foo S H, Khayali M, Bear G, Goldstein M
Neurology. 1980 May;30(5):518-23. doi: 10.1212/wnl.30.5.518.
Twenty-eight patients with Parkinson disease (PD) were treated with bromocriptine for at least 2 years (mean, 2.8 years; range, 2 to 5 years). All of them had first been treated with levodopa (alone or combined with carbidopa, as Sinemet) for 7.4 years (range, 1 to 10 years). At the time bromocriptine was started, all were showing increasing disability. In these patients, attempts to increase levodopa resulted in adverse effects, and attempts to decrease levodopa resulted in increased parkinsonism. Bromocriptine (mean daily dose, 56 mg) was added to levodopa and resulted in improvement of at least one stage (Hoehn and Yahr scale) in 21 of the patients. After 2 years, five of these patients continue to maintain this improvement. The remaining patients, although there has been deterioration, maintain some of their original improvement. Bromocriptine, when added to levodopa, results in improvement that is maintained, in part, for at least 2 years. The ratio of bromocriptine to levodopa has to be periodically readjusted.
28例帕金森病（PD）患者接受溴隐亭治疗至少2年（平均2.8年；范围2至5年）。他们均首先接受左旋多巴治疗（单独使用或与卡比多巴联合使用，即息宁）7.4年（范围1至10年）。开始使用溴隐亭时，所有患者均表现出残疾程度加重。在这些患者中，增加左旋多巴剂量会导致不良反应，而减少左旋多巴剂量则会使帕金森症状加重。在左旋多巴基础上加用溴隐亭（平均日剂量56mg）后，21例患者的病情改善至少一个阶段（霍恩和雅尔分级量表）。2年后，其中5例患者持续保持这种改善。其余患者虽有病情恶化，但仍维持部分最初的改善效果。左旋多巴加用溴隐亭后可带来改善，且这种改善至少部分持续2年。必须定期调整溴隐亭与左旋多巴的比例。
